Stay updated on PemCab in Cisplatin-Ineligible UC Clinical Trial
Sign up to get notified when there's something new on the PemCab in Cisplatin-Ineligible UC Clinical Trial page.

Latest updates to the PemCab in Cisplatin-Ineligible UC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the completed PemCab study of cabozantinib plus pembrolizumab for advanced urothelial carcinoma, with its study details, participant criteria, outcome measures, and supporting documents.SummaryDifference55%

- Check19 days agoChange DetectedThe displayed ClinicalTrials.gov revision changed from v3.7.2 to v3.8.0; the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe footer now shows site revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the detailed study content with a minimal error screen. Previously visible items such as study details, locations, and contacts are not shown in this view.SummaryDifference20%

Stay in the know with updates to PemCab in Cisplatin-Ineligible UC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PemCab in Cisplatin-Ineligible UC Clinical Trial page.